Based: San Diego
Stock symbol: RCPT
Range: $14 to $16
IPO price: $14
Close Oct. 17: $33.13
Change: Up 136%
Raised: $72.8 million

The scoop: Analysts expect the market for oral multiple sclerosis therapies to explode over the coming years as new pills take the place of injected therapies for many patients. Receptos' share price didn't wait for the market, though, or late-stage data on its oral therapy, RPC1063. Next year the biotech expects to report data from the midstage portion of a Phase II/III trial for the candidate in patients with relapsing MS. The late-stage portion of the study could take off in 2013, according to a regulatory filing, and investigators are also studying the therapy for inflammatory bowel disease. This year the developer in-licensed an IL-13 antibody from AbbVie ($ABBV), targeting a Phase II study of the candidate for treating a rare respiratory ailment called eosinophilic esophagitis, with AbbVie holding onto an option on the drug.  

For more:
Biotech Receptos claims $73M IPO prize to fuel oral MS contender
Receptos hits biotech IPO queue with oral MS contender


Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.